The global diabetic nephropathy market revenue was around US$ 2 billion in 2022 and is estimated to reach US$ 3.37 billion by 2031, growing at a compound annual growth rate (CAGR) of 6% during the forecast period from 2023 to 2031.
Diabetic nephropathy is a long-term kidney disorder that can affect individuals with diabetes. It happens when high blood glucose levels injure kidney functions. It can occur in individuals with type-2 diabetes. Diabetic nephropathy is caused by damage to the smallest blood vessels. When tiny blood vessels start to develop damage, both kidneys begin to spread proteins into the urine.
Market Driving Factors
A strong pipeline of drugs is estimated to drive market growth. There is increasing evidence suggesting that sodium-glucose cotransporter 2 (SGLT2) inhibitors and Glucagon-like peptide 1 (GLP-1) receptors are predicted to control chronic kidney disease. In addition, there is an increase in the number of various drug discovery studies being assessed. Furthermore, the existing therapeutic management of diabetic nephropathy includes blockade of the renin-angiotensin-aldosterone and glycemic control system. However, numerous patients ultimately progress to end-stage renal disease.
Growing healthcare costs, especially in developing nations, play a major role in the market growth. Increased healthcare funding enables improved accessibility to healthcare facilities, medications, diagnostics, and treatment chances for people with diabetic nephropathy.
Shortage of qualified medical personnel in developing and underdeveloped nations, and there have been obstacles to the sales of medications for diabetic nephropathy. As a result, this factor hinders market expansion.
Regional Analysis
Europe dominated the market in terms of the largest share and is estimated to continue its dominance over the forecast period. This can be majorly attributed to the surge in government and pharmaceutical organizations' efforts to increase awareness of kidney disease as well as the presence of generic manufacturers.
Asia-Pacific dominates the market in terms of the highest growth rate due to the projection period. This is largely due to the surge in healthcare spending, rising market awareness of new diabetic drugs, and increasing the number of hospitals in the region.
Segmentation Insights
Distribution Channel Insight
The hospital pharmacy segment dominates the market in terms of the largest share. This is because chronic kidney condition has become common worldwide and individuals suffering from chronic kidney disorder have an augmented risk of health complications.
The drug store & retail pharmacies segment dominates the market in terms of the largest share. This is because of the procurement of prescription drugs and the refills of the prescribed medicines. Furthermore, the initial phase 3 symptoms associated with diabetic nephropathies, such as inflammation, can also be treated with Over-the-counter (OTC) drugs that can be simply procured from retail pharmacies.
Drugs Class Insight
The angiotensin receptor blockers segment dominated the market in terms of the highest share. The growth is attributed to several benefits associated with the use of angiotensin receptor blockers. For instance, it controls and delays the development of nephropathy among patients suffering from microalbuminuria, and type 2 diabetes and aids diabetic patients in preventing the development of any type of complications.
The angiotensin-converting enzyme inhibitors segment dominates the market in terms of the rate. Several clinical studies have demonstrated the clinical efficiency of ACE inhibitors in slowing the progression of chronic kidney disease (CKD) to end-stage renal disorders. In addition, such clinical advantages are leading to the increasing acceptance of ACE inhibitors for the treatment of diabetic nephropathy, ultimately contributing to market growth.
Type Insight
The type-2 diabetes segment dominates the market in terms of the highest revenue. This is mainly due to the high prevalence of Diabetic Nephropathy (DN) cases in adults aged 20 and older with type 2 diabetes globally. In addition, the number of individuals with type 2 diabetes is growing, though faster in low- and middle-income countries than in high-income countries. Therefore, the increasing incidence of diabetes type-2 patients may drive the market.
Prominent Companies
Segmentation Outline
The global diabetic nephropathy market segmentation focuses on the Distribution Channel, Drugs Class, Type, and Region.
By Distribution Channel
By Drugs Class
By Type
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL DIABETIC NEPHROPATHY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: DIABETIC NEPHROPATHY MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL DIABETIC NEPHROPATHY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
5.1 OVERVIEW
5.2 HOSPITAL PHARMACY
5.3 ONLINE PROVIDERS
5.4 DRUG STORES AND RETAIL PHARMACY
6 GLOBAL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS
6.1 OVERVIEW
6.2 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
6.3 ANGIOTENSIN RECEPTOR BLOCKERS
6.4 CALCIUM CHANNEL BLOCKER
6.5 DIURETICS
6.6 RENIN INHIBITOR
6.7 OTHERS
7 GLOBAL DIABETIC NEPHROPATHY MARKET, BY TYPE
7.1 OVERVIEW
7.2 TYPE-1 DIABETES
7.3 TYPE-2 DIABETES
8 GLOBAL DIABETIC NEPHROPATHY MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL DIABETIC NEPHROPATHY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 ASTRAZENECA PLC
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ABBOTT LABORATORIES
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 ABBVIE INC
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 MERCK & CO
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 SANOFI
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 NOVARTIS AG
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 PFIZER INC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 ELI LILLY AND COMPANY
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 REATA PHARMACEUTICALS
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 BAYER AG
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved